<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1852">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137054</url>
  </required_header>
  <id_info>
    <org_study_id>R5458-ONC-2012</org_study_id>
    <secondary_id>2020-004638-39</secondary_id>
    <nct_id>NCT05137054</nct_id>
  </id_info>
  <brief_title>REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability, and identify the&#xD;
      recommended dose of REGN5458 for the expansion portion in combination with each one of the&#xD;
      following cancer treatments:&#xD;
&#xD;
        -  Daratumumab plus dexamethasone (Dd: Cohort 1)&#xD;
&#xD;
        -  Carfilzomib plus dexamethasone (Kd: Cohort 2)&#xD;
&#xD;
        -  Lenalidomide plus dexamethasone (Rd: Cohort 3)&#xD;
&#xD;
        -  Bortezomib plus dexamethasone Vd: (Cohort 4)&#xD;
&#xD;
      The secondary objectives of the study for each cohort are:&#xD;
&#xD;
        -  To assess the preliminary anti-tumor activity by International Myeloma Working Group&#xD;
           (IMWG) criteria&#xD;
&#xD;
        -  To measure the depth and durability of response&#xD;
&#xD;
        -  To evaluate the pharmacokinetic (PK) properties of REGN5458 when given in combination&#xD;
           with Dd, Kd, Rd, and Vd&#xD;
&#xD;
        -  To evaluate immunogenicity of REGN5458 when given in combination with Dd, Kd, Rd, and Vd&#xD;
&#xD;
        -  Describe the overall survival (OS) of the participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 28, 2022</start_date>
  <completion_date type="Anticipated">March 16, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pre-defined safety criteria (dose-limiting toxicities (DLTs)) from the first dose through the end of the DLT observation period</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Dose finding portion only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>As measured by chemistry, hematology, urinalysis and pregnancy testing&#xD;
Dose finding portion Dose expansion portion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) using the IMWG criteria</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as measured using the IMWG criteria</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of minimal residual disease (MRD) negative status using the IMWG criteria</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of REGN5458 in the serum over time</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence over time of anti-drug antibodies (ADAs) to REGN5458</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Dose finding portion Dose expansion portion</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: R5458 + Dd Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R5458 + Daratumumab and dexamethasone (Dd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: R5458 + Kd Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R5458 + Carfilzomib and dexamethasone (Kd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: R5458 + Rd Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R5458 + Lenalidomide and dexamethasone (Rd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: R5458 + Vd Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R5458 + Bortezomib and dexamethasone (Vd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN5458</intervention_name>
    <description>REGN5458 is administered by intravenous (IV) infusion</description>
    <arm_group_label>Cohort 1: R5458 + Dd Combo</arm_group_label>
    <arm_group_label>Cohort 2: R5458 + Kd Combo</arm_group_label>
    <arm_group_label>Cohort 3: R5458 + Rd Combo</arm_group_label>
    <arm_group_label>Cohort 4: R5458 + Vd Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection is administered after a minimum of 2 cycles of IV administration at the investigator's discretion.</description>
    <arm_group_label>Cohort 1: R5458 + Dd Combo</arm_group_label>
    <other_name>Darzalex®; Darzalex Faspro™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib is administered by IV infusion</description>
    <arm_group_label>Cohort 2: R5458 + Kd Combo</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide is administered by mouth (PO) as a capsule</description>
    <arm_group_label>Cohort 3: R5458 + Rd Combo</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib is administered by IV infusion or SC injection</description>
    <arm_group_label>Cohort 4: R5458 + Vd Combo</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone is administered by mouth as a capsule or by IV administration.</description>
    <arm_group_label>Cohort 1: R5458 + Dd Combo</arm_group_label>
    <arm_group_label>Cohort 2: R5458 + Kd Combo</arm_group_label>
    <arm_group_label>Cohort 3: R5458 + Rd Combo</arm_group_label>
    <arm_group_label>Cohort 4: R5458 + Vd Combo</arm_group_label>
    <other_name>Decadron®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          2. Relapsed/refractory multiple myeloma (MM): Progression of disease following at least 3&#xD;
             lines of therapy, or least 2 lines of therapy and either:&#xD;
&#xD;
               -  prior exposure to at least 1 anti-CD38 antibody, 1 IMiD and 1 PI or&#xD;
&#xD;
               -  double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD.&#xD;
                  Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated.&#xD;
                  However, patients cannot be refractory to an anti-CD38 antibody-containing&#xD;
                  regimen. In addition, patients must have a 6-month washout from prior anti-CD38&#xD;
                  antibody therapy.&#xD;
&#xD;
             Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the&#xD;
             approved full dose. However, patients cannot be refractory to a carfilzomib-containing&#xD;
             regimen. In addition, patients must have a 6-month washout from prior carfilzomib&#xD;
             therapy.&#xD;
&#xD;
             Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the&#xD;
             approved full dose. However, a patient cannot be refractory to any combination regimen&#xD;
             that included 25 mg of lenalidomide. In addition, patients must have a 6-month washout&#xD;
             from prior lenalidomide therapy (including maintenance therapy).&#xD;
&#xD;
             Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the&#xD;
             approved full dose. However, a patient cannot be refractory to any combination regimen&#xD;
             including the approved induction dose of bortezomib. In addition, patients must have a&#xD;
             6-month washout from prior bortezomib therapy.&#xD;
&#xD;
          3. Participants must have measurable disease and as defined in the protocol for response&#xD;
             assessment as per the 2016 International Myeloma Working Group (IMWG) response&#xD;
             assessment criteria&#xD;
&#xD;
          4. Adequate creatinine clearance, hematologic and hepatic functions, as defined in&#xD;
             protocol&#xD;
&#xD;
          5. Life expectancy of at least 6 months&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma&#xD;
             associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma),&#xD;
             or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,&#xD;
             and skin changes)&#xD;
&#xD;
          2. Participants with known MM brain lesions or meningeal involvement&#xD;
&#xD;
          3. Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days&#xD;
             prior to first administration of study drug regimen, whichever is shorter.&#xD;
&#xD;
          4. History of allogeneic stem cell transplantation, or autologous stem cell&#xD;
             transplantation within 12 weeks of the start of study drug regimen&#xD;
&#xD;
          5. For participants with peripheral neuropathy grade ≥2 receiving bortezomib-based&#xD;
             treatment (cohort 4 only)&#xD;
&#xD;
          6. Prior treatment with BCMA-directed immunotherapies, including any chimeric antigen&#xD;
             receptor T cell (CAR T) therapy (Note: BCMA antibody-drug conjugates are not excluded)&#xD;
&#xD;
          7. History of neurodegenerative condition or central nervous system (CNS) movement&#xD;
             disorder or participants with a history of seizure within 12 months prior to study&#xD;
             enrollment are excluded&#xD;
&#xD;
          8. Live or attenuated vaccination within 28 days prior to first study drug regimen&#xD;
             administration with a vector that has replicative potential&#xD;
&#xD;
          9. Cardiac ejection fraction &lt;40% by echocardiogram (Echo) or multigated acquisition&#xD;
             (MUGA) scan.&#xD;
&#xD;
         10. Pregnant or breasting feeding women or women of childbearing potential (WOCBP) with&#xD;
             positive pregnancy test result&#xD;
&#xD;
         11. WOCBP or men who are unwilling to practice highly effective contraception prior to the&#xD;
             initial dose/start of the first treatment, during the study, and for at least 6 months&#xD;
             after the last dose.&#xD;
&#xD;
        NOTE: Other protocol defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Multiple Myeloma (R/R MM)</keyword>
  <keyword>B-cell maturation antigen (BCMA)</keyword>
  <keyword>Anti-CD3 monoclonal antibodies (mAbs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

